LANADELUMAB
lanadelumab 300 mg/2 mL injection, 2 mL syringe
LANADELUMAB (12790E)
12790E
Manner of administration:Injection
Restriction
Indication: Chronic treatment of hereditary angioedema Types 1 or 2
Treatment phase: Initial 1: New patient (commencing with no previous treatment with C1-INH for routine
prophylaxis)
Restriction
Indication: Chronic treatment of hereditary angioedema Types 1 or 2
Treatment phase: Initial 2: New patient (commencing from National Blood Authority-funded C1-INH)
Restriction
Indication: Chronic treatment of hereditary angioedema Types 1 or 2
Treatment phase: Initial 3: New patient (transitioning from PBS-subsidised garadacimab)
Restriction
Indication: Chronic treatment of hereditary angioedema Types 1 or 2
Treatment phase: Continuing preventative treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $18,603.03 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Takhzyro | |||||